Why Sequenom (SQNM) Stock Was Up Today

NEW YORK (TheStreet) -- Sequenom, Inc. (SQNM) shares finished trading Monday up 9.1% to $3.34 following news that the company gained pre-market FDA clearance for its IMPACT genotyping test.

The noninvasive prenatel test analyzes chromosonal material in cell free DNA for pregnant women at an increased risk for fetal chromosonal abnormalities.

The San Diego-based company formed a licencing agreement with Quest Diagnostics (DGX) -- expected to make the test available by the third quarter-- to expand patient access to the test.

Must ReadWarren Buffett's 25 Favorite Stocks 

SQNM Chart

SQNM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%